The global Allergy Immunotherapies Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Treatment (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), By Allergy (Allergic rhinitis, Allergic asthma, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).
The Allergy Immunotherapies Market in 2024 emphasizes the growing demand for personalized allergy treatments and immunomodulatory interventions to address allergic conditions such as allergic rhinitis, asthma, and food allergies. Immunotherapy options, including subcutaneous allergen immunotherapy (SCIT), sublingual immunotherapy (SLIT), and allergen-specific biologics, offer targeted immune responses, desensitization to allergens, and long-term symptom relief for allergy sufferers. Patient-centric approaches, precision medicine initiatives, and allergy diagnostics drive advancements in allergy immunotherapies and allergy management protocols.
The global Allergy Immunotherapies Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Allergy Immunotherapies Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Allergy Immunotherapies Industry include- ALK-Abello A/S, Allergy Therapeutics, Allovate Llc, Biomay AG, HAL Allergy Group, Jubliant Pharma, Leti Pharma, Merck KGaA, Stallergenes Greer, Torii Pharmaceutical Co. Ltd.
In the Allergy Immunotherapies market, a prominent trend is the increasing focus on precision medicine and personalized treatment approaches. With advancements in understanding allergic mechanisms and immune responses, there's a shift towards developing tailored immunotherapies that target specific allergens and individual patient profiles, offering enhanced efficacy and safety in allergy management.
A significant driver for the Allergy Immunotherapies market is the rising prevalence of allergic disorders and sensitivities. As allergic conditions such as asthma, allergic rhinitis, and food allergies continue to affect millions worldwide, there is a growing demand for effective long-term solutions beyond symptomatic relief, driving the adoption of allergy immunotherapies as disease-modifying treatments.
An opportunity exists in expanding the Allergy Immunotherapies market through the development of novel therapeutic modalities and delivery systems. Innovations such as sublingual immunotherapy tablets, oral mucosal immunotherapy, and nanoparticle-based allergen delivery platforms present avenues for improving treatment compliance, efficacy, and patient experience, thereby expanding market reach and addressing unmet needs in allergy management.
Within the segmentation of Allergy Immunotherapies, the segment of Sublingual Immunotherapy (SLIT) Tablets for Allergic Rhinitis stands out as the fastest-growing. This growth is propelled by several key factors. SLIT tablets offer a convenient and effective alternative to traditional allergy shots (Subcutaneous Immunotherapy - SCIT) for the treatment of allergic rhinitis, a common allergic condition affecting millions worldwide. SLIT tablets are administered orally, allowing patients to self-administer treatment at home without the need for frequent clinic visits. This convenience factor significantly improves patient adherence and compliance, leading to better treatment outcomes. Moreover, SLIT tablets have demonstrated efficacy in reducing allergy symptoms, improving quality of life, and providing long-term relief from allergic rhinitis symptoms. Additionally, advancements in SLIT tablet formulations and delivery systems have enhanced their safety and efficacy profiles, further driving their adoption among healthcare providers and patients. Furthermore, the increasing prevalence of allergic rhinitis globally, coupled with the growing awareness of the benefits of SLIT tablets, fuels the demand for this innovative allergy immunotherapy. As a result, the segment of SLIT Tablets for Allergic Rhinitis emerges as the fastest-growing segment within the Allergy Immunotherapies market, offering patients a convenient and effective treatment option for managing allergic rhinitis symptoms.
By Treatment
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
-Tablets
-Drops
By Allergy
Allergic rhinitis
Allergic asthma
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
ALK-Abello A/S
Allergy Therapeutics
Allovate Llc
Biomay AG
HAL Allergy Group
Jubliant Pharma
Leti Pharma
Merck KGaA
Stallergenes Greer
Torii Pharmaceutical Co. Ltd
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Allergy Immunotherapies Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Allergy Immunotherapies Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Allergy Immunotherapies Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Allergy Immunotherapies Market Size Outlook, $ Million, 2021 to 2030
3.2 Allergy Immunotherapies Market Outlook by Type, $ Million, 2021 to 2030
3.3 Allergy Immunotherapies Market Outlook by Product, $ Million, 2021 to 2030
3.4 Allergy Immunotherapies Market Outlook by Application, $ Million, 2021 to 2030
3.5 Allergy Immunotherapies Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Allergy Immunotherapies Industry
4.2 Key Market Trends in Allergy Immunotherapies Industry
4.3 Potential Opportunities in Allergy Immunotherapies Industry
4.4 Key Challenges in Allergy Immunotherapies Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Allergy Immunotherapies Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Allergy Immunotherapies Market Outlook by Segments
7.1 Allergy Immunotherapies Market Outlook by Segments, $ Million, 2021- 2030
By Treatment
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
-Tablets
-Drops
By Allergy
Allergic rhinitis
Allergic asthma
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
8 North America Allergy Immunotherapies Market Analysis and Outlook To 2030
8.1 Introduction to North America Allergy Immunotherapies Markets in 2024
8.2 North America Allergy Immunotherapies Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Allergy Immunotherapies Market size Outlook by Segments, 2021-2030
By Treatment
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
-Tablets
-Drops
By Allergy
Allergic rhinitis
Allergic asthma
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
9 Europe Allergy Immunotherapies Market Analysis and Outlook To 2030
9.1 Introduction to Europe Allergy Immunotherapies Markets in 2024
9.2 Europe Allergy Immunotherapies Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Allergy Immunotherapies Market Size Outlook by Segments, 2021-2030
By Treatment
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
-Tablets
-Drops
By Allergy
Allergic rhinitis
Allergic asthma
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
10 Asia Pacific Allergy Immunotherapies Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Allergy Immunotherapies Markets in 2024
10.2 Asia Pacific Allergy Immunotherapies Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Allergy Immunotherapies Market size Outlook by Segments, 2021-2030
By Treatment
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
-Tablets
-Drops
By Allergy
Allergic rhinitis
Allergic asthma
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
11 South America Allergy Immunotherapies Market Analysis and Outlook To 2030
11.1 Introduction to South America Allergy Immunotherapies Markets in 2024
11.2 South America Allergy Immunotherapies Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Allergy Immunotherapies Market size Outlook by Segments, 2021-2030
By Treatment
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
-Tablets
-Drops
By Allergy
Allergic rhinitis
Allergic asthma
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
12 Middle East and Africa Allergy Immunotherapies Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Allergy Immunotherapies Markets in 2024
12.2 Middle East and Africa Allergy Immunotherapies Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Allergy Immunotherapies Market size Outlook by Segments, 2021-2030
By Treatment
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
-Tablets
-Drops
By Allergy
Allergic rhinitis
Allergic asthma
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
ALK-Abello A/S
Allergy Therapeutics
Allovate Llc
Biomay AG
HAL Allergy Group
Jubliant Pharma
Leti Pharma
Merck KGaA
Stallergenes Greer
Torii Pharmaceutical Co. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Treatment
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
-Tablets
-Drops
By Allergy
Allergic rhinitis
Allergic asthma
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
The global Allergy Immunotherapies Market is one of the lucrative growth markets, poised to register a 8.5% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
ALK-Abello A/S, Allergy Therapeutics, Allovate Llc, Biomay AG, HAL Allergy Group, Jubliant Pharma, Leti Pharma, Merck KGaA, Stallergenes Greer, Torii Pharmaceutical Co. Ltd
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume